CollPlant Biotechnologies (CLGN) Net Income towards Common Stockholders (2017 - 2026)
CollPlant Biotechnologies (CLGN) posted Net Income towards Common Stockholders of -$3.1 million for Q1 2026, up 90.26% on a QoQ basis from -$32.0 million in Q4 2025, and down 89.02% year-over-year from -$28.4 million in Q1 2025.
CollPlant Biotechnologies (CLGN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 89.02% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.4 million (down 24.2% YoY) and the FY2025 annual result came in at -$39.9 million, down 1.67% from the prior year.
- Net Income towards Common Stockholders was -$3.1 million for Q1 2026 at CollPlant Biotechnologies, up from -$32.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5.7 million in Q2 2023 and bottomed at -$32.0 million in Q4 2025.
- A 5-year average of -$6.6 million and a median of -$3.5 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 235.65% — and 2025, when it tumbled 138.07%.
- CollPlant Biotechnologies' Net Income towards Common Stockholders stood at -$27.1 million in 2022, then climbed by 10.34% to -$24.3 million in 2023, then declined by 9.89% to -$26.7 million in 2024, then slipped by 19.6% to -$32.0 million in 2025, then jumped by 90.26% to -$3.1 million in 2026.
- Business Quant data shows CLGN's Net Income towards Common Stockholders at -$3.1 million in Q1 2026, -$32.0 million in Q4 2025, and -$3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | -0.68 |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | -453.82 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | -3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -3.12 Mn |
| Dec 31, 2025 | -31.98 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 30, 2025 | -1.65 Mn |
| Dec 31, 2024 | -26.74 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | -24.34 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | -27.14 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -4.19 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | -227.59 Mn |
| Sep 30, 2021 | 71.91 Mn |
| Jun 30, 2021 | -2.98 Mn |